

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**UNAUDITED FINANCIAL INFORMATION OF SHANGHAI MICROPORT
 ENDOVASCULAR MEDTECH (GROUP) CO., LTD.
 FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2021**

Set out below is the key unaudited financial information of Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (“EV MedTech”) for the nine months ended 30 September 2021. EV MedTech is owned as to 46.34% by the Company and its results are consolidated with the financial statements of the Company. The shares of EV MedTech are listed on the science and technology innovation board of the Shanghai Stock Exchange.

	For the nine months ended 30 September 2021 RMB'000	For the nine months ended 30 September 2020 RMB'000	Change %
Revenue	510,158.4	328,184.1	55.45
Profit	291,286.0	189,448.1	53.76
Net profit attributable to equity owners of EV MedTech	249,984.8	162,403.3	53.93
	As of 30 September 2021 RMB'000	As of 31 December 2020 RMB'000	Change %
Total assets	1,660,723.7	1,376,066.0	20.69
Total equity attributable to equity owners of EV MedTech	1,419,176.7	1,233,972.2	15.01

Shareholders and investors are reminded that the financial information above was prepared in accordance with PRC accounting standards and are limited solely to the operation of EV MedTech and are unrelated to the other subsidiaries of the Group. Such information is unaudited, and does not (a) exclude intra-group transactions, (b) include all the business of the Group, and (c) represent or provide a full picture of the operation or status of the Group. **Shareholders and potential investors of the Company are reminded to exercise caution when dealing in the securities of the Company.**

By order of the Board
MicroPort Scientific Corporation
Dr. Zhaohua Chang
Chairman

Shanghai, the PRC, 28 October 2021

As at the date of this announcement, the executive Director is Dr. Zhaohua Chang; the non-executive Directors are Mr. Norihiro Ashida, Dr. Yasuhisa Kurogi and Mr. Hongliang Yu; and the independent non-executive Directors are Mr. Jonathan H. Chou, Dr. Guoen Liu and Mr. Chunyang Shao.

* *For identification purpose only*